Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Intangibles (2024 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Intangibles for 2 consecutive years, with -$600000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Intangibles changed N/A to -$600000.0 in Q4 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a N/A change, with the full-year FY2024 number at $600000.0, changed N/A from a year prior.
  • Change in Intangibles was -$600000.0 for Q4 2025 at Anika Therapeutics, down from $600000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $600000.0 in Q3 2024 to a low of -$600000.0 in Q4 2025.